
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics Inc, a clinical-stage biopharmaceutical company, has outlined a compelling perspective on its stock primarily due to the promising data surrounding its product candidate, ML-007C-MA, which targets central receptors associated with schizophrenia and Alzheimer's disease psychosis while mitigating peripheral side effects. The company reported that Cobenfy, related to its muscarinic agonist portfolio, achieved US revenues of $155 million in its first full launch year, significantly outpacing competitors and underscoring the potential for a larger total addressable market (TAM) within the muscarinic class of drugs. Additionally, improvements in safety and tolerability profiles, particularly in the context of treatment-related adverse effects and cognitive function, provide a strong foundation for MapLight Therapeutics's future growth and competitive positioning in the biopharmaceutical space.
Bears say
MapLight Therapeutics Inc. is facing significant challenges in the competitive schizophrenia market, particularly due to its delayed entry and the negative safety profile of its product candidate, ML-007C-MA, which may hinder market penetration. The lower expectations surrounding its upcoming Phase 3 readout and concerns about potential conduct issues in the clinical trials further contribute to skepticism among investors. Additionally, the company's current market capitalization of approximately $800 million is viewed as overvalued given the potential for a dramatically reduced discounted cash flow (DCF) value per share should the probability of approval decrease significantly, highlighting heightened risk associated with its financial outlook.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares